HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sandra Li Selected Research

oxyamylose (COAM)

1/2014Interference with glycosaminoglycan-chemokine interactions with a probe to alter leukocyte recruitment and inflammation in vivo.
8/2012Glycosaminoglycan mimicry by COAM reduces melanoma growth through chemokine induction and function.
11/2010Myeloid cells are tunable by a polyanionic polysaccharide derivative and co-determine host rescue from lethal virus infection.
4/2009Inflammatory rather than infectious insults play a role in exocrine tissue damage in a mouse model for coxsackievirus B4-induced pancreatitis.
10/2008Virus entry inhibition by chlorite-oxidized oxyamylose versus induction of antiviral interferon by poly(I:C).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sandra Li Research Topics

Disease

5Neoplasms (Cancer)
01/2021 - 07/2010
4Infections
11/2010 - 10/2008
3Melanoma (Melanoma, Malignant)
01/2015 - 08/2012
1Thymoma (Thymic Carcinoma)
11/2014
1Inflammation (Inflammations)
01/2014
1Neuroinflammatory Diseases
10/2012
1Lymphadenopathy
05/2011
1Autoimmune Diseases (Autoimmune Disease)
05/2011
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
05/2011
1Splenomegaly
05/2011
1Autoimmune Lymphoproliferative Syndrome
05/2011
1Virus Diseases (Viral Diseases)
11/2010
1Esophageal Neoplasms (Esophageal Cancer)
07/2010
1Adenocarcinoma
07/2010
1Neoplasm Metastasis (Metastasis)
07/2010
1Colonic Neoplasms (Colon Cancer)
07/2010
1Colorectal Neoplasms (Colorectal Cancer)
07/2010
1Carcinoma (Carcinomatosis)
07/2010
1Esophageal Squamous Cell Carcinoma
07/2010
1Body Weight (Weight, Body)
08/2009
1Pancreatitis
04/2009

Drug/Important Bio-Agent (IBA)

5oxyamylose (COAM)IBA
01/2014 - 10/2008
5ChemokinesIBA
01/2014 - 07/2010
4Antiviral Agents (Antivirals)IBA
08/2012 - 10/2008
3Proteins (Proteins, Gene)FDA Link
01/2015 - 07/2010
2HMGN1 Protein (HMGN1)IBA
01/2015 - 11/2014
2GlycosaminoglycansIBA
01/2014 - 08/2012
1GelsIBA
01/2015
1AntigensIBA
01/2015
1AlarminsIBA
01/2015
1DNA (Deoxyribonucleic Acid)IBA
01/2015
1A-Form DNA (A-DNA)IBA
11/2014
1OvalbuminIBA
11/2014
1Complement System Proteins (Complement)IBA
10/2012
1Matrix Metalloproteinase InhibitorsIBA
05/2011
1AutoantibodiesIBA
05/2011
1Matrix Metalloproteinase 9 (Gelatinase B)IBA
05/2011
1Matrix Metalloproteinases (MMPs)IBA
05/2011
1PolymersIBA
11/2010
1Polysaccharides (Glycans)IBA
11/2010
1Peptidoglycan (Murein)IBA
07/2010
1Phorbol EstersIBA
07/2010
1ImmunosorbentsIBA
07/2010
1EnzymesIBA
07/2010
1Interferon-gamma (Interferon, gamma)IBA
07/2010
1InterleukinsIBA
07/2010
1LigandsIBA
07/2010
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
07/2010
1Double-Stranded RNA (RNA, Double Stranded)IBA
07/2010
1Toll-Like Receptors (Toll-Like Receptor)IBA
07/2010
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
07/2010
1Interleukin-8 (Interleukin 8)IBA
07/2010
1Chemokine CXCL12IBA
07/2010
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2010
1Pharmaceutical PreparationsIBA
08/2009
1Chloroquine (Aralen)FDA LinkGeneric
08/2009
1Carboxylic AcidsIBA
04/2009

Therapy/Procedure

1Therapeutics
01/2021
1Investigational Therapies (Experimental Therapy)
10/2012